Company intelligence / Profile preview

Vanrx Pharmasystems

Burnaby, British Columbia, Canadaprnewswire.com ↗

Ownership: Private
Employees: ~120
Development stage: Commercial

Overview

Vanrx developed advanced robotic aseptic filling systems that automate the packaging of injectable drugs into vials, syringes, and cartridges using gloveless isolators and machine vision. Their platforms are used by leading biopharmaceutical companies to enable rapid changeover between formats and support next-generation therapies including personalized medicines. The company was acquired by Cytiva in February 2021.

Modalities: Device (Aseptic filling systems for injectable drugs)Cell therapy solutions (enables fill-finish for cell therapies)Biologic (supports biologics manufacturing workflows)Small molecule (applicable to small molecule injectables)
Industry: Contract Manufacturing Organization

Partnerships

Integration with major biopharma manufacturers as customersnow part of Cytiva's global network

Beyond the preview

Go deeper on Vanrx Pharmasystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vanrx Pharmasystems.

Explore the full profile